Tag: Room

  • Key dates for nursing and midwifery discussions in May 2020

    Key dates for nursing and midwifery discussions in May 2020

    WHO has declared 2020 as the International Year of the Nurse and the Midwife to mark the bicentenary of the birth of the founder of modern nursing, Florence Nightingale and to recognize the critical contribution both professions make to global health. May is a key moment to catalyse high-level dialogue and collaborative engagements for moving forward the findings of The State of the World’s Nursing Report, which will be launched on World Health Day, 7 April 2020, as part of the activities of the International Year of the Nurse and the Midwife.

    Key dates for May 2020

    Ninth WHO Global Forum for Government Chief Nursing and Midwifery Officers (GCNMOs) and the Eighth Triad Meeting, 13–15 May, Geneva– organized jointly by WHO, the International Confederation of Midwives and the International Council of Nurses. The meetings will be held at the Centre International de Conférence (CICG), immediately prior to the Seventy-third World Health Assembly. (by invitation only)

    Health for All, Film Festival, 16 May (PM), Geneva – special focus on nursing and midwifery film submission

    Walk the Talk, 17 May (AM), Geneva – special focus will be given to nurses and midwives in celebration of the International Year of the Nurse and Midwife. We encourage you to register at https://www.who.int/news-room/events/detail/2020/05/17/default-calendar/walk-the-talk-the-health-for-all-challenge

    World Health Assembly 17- 20 May, Geneva

     

    Key dates for nursing and midwifery discussions in May 2020
    Read More
    https://www.who.int/news-room/detail/20-02-2020-key-dates-for-nursing-and-midwifery-discussions-in-may-2020

    Views: 0

  • WHO Action framework to advance universal access to safe, effective and quality assured blood products 2020 -2023

    WHO Action framework to advance universal access to safe, effective and quality assured blood products 2020 -2023

    In response to calls for action, WHO has provided guidelines, physical standards, training and technical support to improve blood product quality, safety and availability in WHO regions and in countries. Despite these actions, progress in blood availability and safety under effective regulation has been slow in many parts of the world.

    For that reason, the WHO Action framework for blood products 2020-2023, proposes a renewed effort to scale up programme implementation to improve global adequacy of blood donation, and universal access to quality and safe blood and blood components for transfusion, and plasma derived medicinal products.

    The Action Framework provides strategic direction to WHO’s work for the years 2020-2023. It identifies six strategic objectives: appropriately structured, well-coordinated and sustainably resourced national blood systems; regulatory capacity to ensure the quality and safety of blood; functioning and efficiently managed blood services; effective implementation of patient blood management to optimize transfusion practices, effective surveillance, haemovigilance and pharmacovigilance, supported by comprehensive and accurate data collection systems; and partnerships, collaboration and information exchange to achieve key priorities and jointly address challenges and emerging threats at global, regional and national levels.

    The Action Framework will improve coordination and collaboration at all levels of WHO. The document will promote and strengthen new and existing partnerships, as areas for collaborative action are clearly identified. Moreover, it demonstrates the need for support to WHO (including sustainable funding) to coordinate the implementation of this ambitious plan. As a result, the Action Framework for blood products will allow WHO to more effectively carry out its mandate on blood, and to increase the impact of WHO activities to strengthen blood systems and blood regulation in countries and regions and eventually to ensure universal access to blood products worldwide.

     

    WHO Action framework to advance universal access to safe, effective and quality assured blood products 2020 -2023
    Read More
    https://www.who.int/news-room/detail/19-02-2020-who-action-framework-to-advance-universal-access-to-safe-effective-and-quality-assured-blood-products-2020–2023

    Views: 0

  • Immunization is the best protection against tick-borne encephalitis

    Immunization is the best protection against tick-borne encephalitis

    immunization-is-the-best-protection-against-tick-borneIn a new position paper, published in the Weekly
    Epidemiological Record today, WHO recommends vaccination against
    tick-borne encephalitis in people of all ages where the disease is
    highly endemic. Where the prevaccination incidence of the disease is
    moderate or low or is limited to particular geographical locations or
    certain outdoor activities, immunization should target individuals in
    the most severely affected groups. People travelling from non-endemic
    areas to endemic areas should be offered vaccination if their visits
    will include extensive outdoor activities.

    Since the incidence of tick-borne encephalitis may vary
    considerably between and even within geographical regions, public
    immunization strategies should be based on risk assessments conducted at
    country, regional or district level, and should be appropriate to the
    local endemic situation.

    Immunization offers the most effective protection against
    tick-borne encephalitis. Currently, there are four widely used vaccines
    of assured quality: FSME-Immun and Encepur, manufactured in Austria and
    Germany respectively, and TBE-Moscow and EnceVir, manufactured in the
    Russian Federation. The four vaccines are considered to be safe and
    efficacious.

    Tick-borne encephalitis virus is an important cause of viral
    infections of the central nervous system in eastern, central and
    northern European countries, and in northern China, Mongolia, and the
    Russian Federation.

    Approximately 10 000–12 000 clinical cases of tick-borne
    encephalitis are reported each year, but this figure is believed to be
    significantly lower than the actual total. Most infections with the
    virus result from tick bites acquired during outdoor activities in
    forested areas.

    Immunization is the best protection against tick-borne encephalitis
    Read More
    https://www.who.int/news-room/detail/19-02-2020-immunization-is-the-best-protection-against-tick-borne-encephalitis

    Views: 0

  • Statement on the meeting of the International Health Regulations (2005) Emergency Committee for Ebola virus disease in the Democratic Republic of the Congo on 12 February 2020

    Statement on the meeting of the International Health Regulations (2005) Emergency Committee for Ebola virus disease in the Democratic Republic of the Congo on 12 February 2020

    The meeting of the Emergency Committee convened by the WHO Director-General under the International Health Regulations (IHR) (2005) to review the current Ebola virus disease (EVD) outbreak in the Democratic Republic of the Congo (DRC) took place on Wednesday, 12 February 2020, from 14:00 to 16:45 Geneva time (CEST).

    Proceedings of the meeting

    Members and advisors of the Emergency Committee were convened by teleconference.

    The Secretariat welcomed the Committee and thanked them for their support. The meeting was turned over to the Chair, Dr Robert Steffen.

    Dr Steffen also welcomed the Committee and gave the floor back to the Secretariat.

    Representatives of WHO’s legal department and the department of compliance, risk management, and ethics briefed the Committee members on their roles and responsibilities.

    Committee members were reminded of their duty of confidentiality and their responsibility to disclose personal, financial, or professional connections that might be seen to constitute a conflict of interest. Each member who was present was surveyed and no conflicts of interest were judged to be relevant to the meeting.

    The Chair then reviewed the agenda for the meeting and introduced the presenters.

    Presentations were made by representatives of the Ministry of Health of the Democratic Republic of the Congo (DRC), the WHO Secretariat, and the UN Ebola Emergency Response Coordinator.

    The current situation in the DRC was reviewed. As of 10 February 2020, there were a total of 3431 cases, of which 3308 were confirmed and 123 were probable. 2253 persons have died (66%). Between 3 and 9 February 2020, three new confirmed cases were reported in Beni Health Zone, North Kivu. These three cases were already registered as contacts and two were under surveillance at the time of detection. More than 2000 contacts are being followed. There has been an increase in the number of security incidents in recent months.

    Challenges that remain include: strengthening of community acceptance for full commitment to response measures; protection of personnel at strategic health checkpoints; improvement of infection prevention and control practices in health facilities; strengthening of the local health system; and comprehensive treatment and support for patients in recovery.

    The WHO Secretariat gave an overview of the epidemiological situation, which shows an overall encouraging trend in case incidence and geographic spread. It was noted that sustaining this progress depends on the security situation and control of the well-known drivers of transmission, particularly in traditional health facilities, and on continued trust and communication with the community.

    A risk communication and community engagement programme has been developed, as has an EVD survivors programme. It is critical to ensure the long-term sustainability of these two initiatives.   

    The situation in countries neighbouring DRC was reviewed, as was preparedness in nonaffected areas of DRC. An EVD operational readiness standardized approach has been implemented in 9 priority countries. More than 2400 alerts have been investigated, and more than 14,600 health workers have been vaccinated.

    The UN Ebola Emergency Response Coordinator gave a brief report on operational support, focused on security challenges and preparations for any resurgence of disease.

    Context and Discussion

    The Committee noted a great deal of progress in the situation since its last meeting and commended the response, under the leadership of the DRC Ministry of Health and the multisectoral coordination commission established in July 2019. Support provided by WHO, UN agencies, nongovernmental organizations and other partners has also contributed to limiting the spread and impact of this virus in a difficult context. An increase in the number of alerts was attributed to strong and proactive community surveillance.

    Conclusions and Advice

    It was the unanimous view of the Committee that this event still constitutes a public health emergency of international concern (PHEIC) under the IHR (2005).

    The Committee acknowledged the revised risk assessment, which puts the risk now as high at national and regional levels, and low at the global level.

    The Committee was concerned that withdrawing the PHEIC now might have adverse consequences for the response efforts through diminishing focus. Additionally, although the primary concern of the Committee is EVD, there are serious ongoing outbreaks of other diseases, including measles and cholera, in DRC. The country continues to need support to combat infectious diseases as well as to strengthen its health system. Further, there remains an urgent need to maintain international solidarity for the response.

    The Committee noted the ongoing discussions about the interpretation in the text of the IHR (2005) of the terms international and regional spread, and about creating an intermediate level of response between the binary possibilities of PHEIC or no PHEIC, in a way that does not require reopening negotiations on the Regulations. The Committee supports these discussions, as an intermediate level would be as useful for gradually ending a PHEIC and for signaling the potential for one to be declared.

    The Committee provided the following advice to the Director-General for his issuance as revised Temporary Recommendations under the IHR (2005).

    For DRC:

    • Sustain the political commitment and multisectoral coordination approach to the response.
    • Continue to engage and build trust with associations of survivors to facilitate rapid detection of any cases arising from exposure to infected bodily fluids of survivors.
    • Continue to strengthen capacity, implementation, and coordination for community awareness and engagement, including a focus on hotspots, preventing resurgence where cases have declined, and to support survivors in their communities.
    • Further enhance the acceptance of response measures and address access and security issues by engaging influencers and decision makers for all interventions.
    • Strengthen measures to prevent and manage nosocomial infections, including systematic mapping of health facilities, targeting of IPC interventions and sustain support to those facilities through monitoring and supervision, including in private-sector and traditional health facilities.
    • Continue cross-border screening and step up monitoring at checkpoints around hotspots and at main roads.
    • Continue to implement and share real-time full-genome genetic sequencing of all new confirmed cases.
    • Strengthen measures to prevent and manage nosocomial infections, including systematic mapping of health facilities, targeting of IPC interventions and sustain support to those facilities through monitoring and supervision.
    • Strengthen preparedness in non-affected provinces of DRC, and more generally strengthen the health system across the country to respond to concurrent health emergencies.
    • Continue to implement optimal vaccine strategies that have proven maximum impact on curtailing the outbreak, as recommended by WHO’s Strategic Advisory Group of Experts (SAGE).

    For countries at risk:

    • At-risk countries should maintain their work with partners to improve their preparedness for detecting and managing imported or locally acquired cases, including the transparent sharing of detailed information on suspect cases, as required by the International Health Regulations (2005), and sharing laboratory samples of suspect cases for confirmatory testing in accordance with WHO norms and guidance.
    • Countries should continue to map population movements and sociological patterns that can predict risk of disease spread.
    • Risk communications and community engagement, especially at points of entry, should be maintained.

    For all countries:

    • As recommended previously, no country should close its borders or place any restrictions on travel and trade.
    • The Committee does not consider entry screening at airports or other ports of entry outside the region to be necessary.

    The Committee emphasized the importance of continued support by WHO and other national and international partners towards the effective implementation and monitoring of these recommendations.

    Based on this advice, the reports made by the affected State Party, and the currently available information, the Director-General accepted the Committee’s assessment and on 12 February 2020 maintained the Ebola outbreak in the Democratic Republic of the Congo as a Public Health Emergency of International Concern (PHEIC).

    The Director-General endorsed the Committee’s advice and issued them as Temporary Recommendations under IHR (2005) to reduce the international spread of Ebola, effective 12 February 2020. The Director-General thanked the Committee Members and Advisors for their advice and requested their reassessment of this situation within two months or earlier if the situation requires.

    Statement on the meeting of the International Health Regulations (2005) Emergency Committee for Ebola virus disease in the Democratic Republic of the Congo on 12 February 2020
    Read More
    https://www.who.int/news-room/detail/12-02-2020-statement-on-the-meeting-of-the-international-health-regulations-(2005)-emergency-committee-for-ebola-virus-disease-in-the-democratic-republic-of-the-congo-on-12-february-2020

    Views: 0

  • Assessing national guidelines on responding to violence against children in the Eastern Mediterranean Region

    Assessing national guidelines on responding to violence against children in the Eastern Mediterranean Region

    In 2019 WHO published guidelines on the health sector response to child maltreatment which describe the role of frontline healthcare providers in recognizing child abuse and neglect and providing appropriate physical and mental health care to child victims of violence. WHO’s Regional Office for the Eastern Mediterranean is using these guidelines to assess and where needed improve existing national health protocols to ensure that child victims of violence receive appropriate support and treatment.

     

    Assessing national guidelines on responding to violence against children in the Eastern Mediterranean Region
    Read More
    https://www.who.int/news-room/detail/18-02-2020-assessing-national-guidelines-on-responding-to-violence-against-children-in-the-eastern-mediterranean-region

    Views: 0

  • International Day of Women and Girls in Science

    International Day of Women and Girls in Science 1

    The theme of the 5th International Day of Women and Girls in Science, was on driving Investment in Equality in Science, Technology and Innovation in the Digitalization Era for Inclusive Green Growth with special focus on Agriculture, Technology and Digital Economy. The commemoration brought together stakeholders from high-level government officials, representatives of international organizations, foundations, private sector, civil society as well as women in science experts from around the world to explore how women in all fields of sciences can accelerate socio-economic sustainable development.

     

    Discussion focused on the interlinkages between gender inequality -specifically in science- digital and technological revolution, and agricultural sector for Sustainable Development. WUN Executive Director Dr Nata Menabde participated in the assembly and highlighted the key role of women and girls in science for health and emphasized on the obstacles women and girls encounter in various levels of health sector – from access to health services, to engagement in health workforce and research. She explained the systematic challenges where women are facing higher health costs than men due to their greater use of health care, as well as the need to extend coverage of health care that deals with the content of benefit packages, to ensure they include a greater range of services for girls and women of all ages. Dr Menabde also shared some conclusions from WHO’s work on nutrition, stressing that gender inequality means girls get less food, are more likely to get sick, and are less likely to be able to attend school, receive an education (including on science) and get a job. However, they are more likely to marry and get pregnant too young, be poorly nourished and have under-nourished babies. In conclusion, she mentioned that healthy women and girls are the cornerstone of healthy societies and proper nutrition is essential to empowering women and girls. Nutrition, through its effect on health and cognitive development, is also vital for academic performance and productivity to ensure healthy economies and socioeconomic development.

     

    Read More
    https://www.who.int/news-room/detail/11-02-2020-international-day-of-women-and-girls-in-science

    Views: 0

  • WHO Global Initiative for Childhood Cancer: progress on all fronts

    WHO Global Initiative for Childhood Cancer: progress on all fronts

     Peru shows the way forward and the courage of Ander Martinez

    “When Ander was diagnosed, I didn´t have the possibility to cover the cost of the treatment. It was very expensive, and I had nothing,” says Rosalina Tocto, 29 years mother of Ander Martínez Tocto. Ander had just been diagnosed with acute leukemia at the young age of 6 years. From the beginning, the odds were stacked against him. He and his family lived in a rural town, six hours from the nearest city. His parents did not have a formal job, placing the family under financial strain.

    Ander and his family were not alone in this situation. “In Peru, nearly 1800 children and adolescents are diagnosed with cancer every year; however, up to 70% will have a late stage, often metastatic due to delays in diagnosis,” says Dr. Juan García, medical chief of the Pediatric Department of in the National Institute of Neoplastic Diseases (INEN) in Lima, Peru. “Most of our patients come from outside Lima and the majority of parents do not have formal employment and therefore do not have any type of insurance.”

    Fortunately, Peru has made a strong commitment to Universal Health Coverage. In 2009, a law was passed to improve access to care by introducing a mandatory health insurance system and registering everyone living in extreme poverty under Seguro Integral de Salud (SIS), regardless of age or circumstance.  

    Dr. Reina Bustamante, Executive Director of the Division of Prevention and Control of Cancer of the MINSA says “UHC is an important step in public health particularly for those who lack public or private insurance like Ander. In this context, we are trying to follow WHO guidance to achieve UHC and ensure all individuals and communities receive the health services they need without suffering financial hardship.”

    In 2019, Peru was selected as a focus country for the WHO Global Initiative for Childhood Cancer as the first focus country in the Region. The Global Initiative aims to improve survival for all children with cancer to at least 60% by 2030 while reducing suffering, altogether with the potential to save an additional one million lives.

    Four main goals were formulated for the national pediatric cancer plan: (1) improve early diagnosis of childhood cancer, (2) decrease treatment abandonment, (3) implement a national pediatric cancer registry and (4) improve the quality of services in pediatric oncology units.

    Dr. Liliana Vasquez, pediatric oncologist who works as an external consultant for the Division of Prevention and Control of Cancer of MINSA said, “Ten working groups have been established to achieve the goals.”

    Dr. Vivian Perez, advisor of the Non-Communicable Diseases Office in PAHO-Peru added “the initial focus for the Initiative will be on six cancers selected as tracers for monitoring progress across the health system, alongside engagement of at least six focus countries with a record of strong political commitment and foundational efforts supporting children with cancer.”

    For Ander, his health care team, the commitments from the government of Peru and partners and Global Initiative have made it possible to be successfully treated and will now allow him to dream of a healthy future though better access to surveillance monitoring and psycho-oncological support aimed at childhood cancer survivors.

    Peru is showing what is possible for all countries. By concerted action and promoting universal health coverage, every child in the world can have access to high-quality care with the greatest likelihood of survival, and every family should be protected from financial hardship. We can do more together. 

     

    WHO Global Initiative for Childhood Cancer: progress on all fronts
    Read More
    https://www.who.int/news-room/detail/14-02-2020-who-global-initiative-for-childhood-cancer-progress-on-all-fronts

    Views: 0

  • Four countries in the African region license vaccine in milestone for Ebola prevention

    The Democratic Republic of the Congo (DRC), Burundi, Ghana and Zambia have licensed an Ebola vaccine, just 90 days after World Health Organization (WHO) prequalification. Registration of the vaccine is expected in additional countries in the coming weeks.

    The licensing of the vaccine means that the manufacturer can stockpile and widely distribute this vaccine to African countries at risk of Ebola virus disease outbreaks. Once licensed doses are available, use of the vaccine will not require clinical trial or other research protocols.

    “The approval of the Ebola vaccine by these countries is another milestone in the fight against this unforgiving disease,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus. “Africa has rallied to cement hard-fought progress to keep its people safe from Ebola.”

    WHO accelerated the licensing and roll-out of the Ebola vaccine by certifying that it met the organization’s standards for quality, safety and efficacy in its fastest vaccine prequalification process ever, announced in November 2019.

    The speed with which this has been achieved has been made possible by a different approach, where national licensing procedures were done in parallel based on one single scientific review process. Usually, these process are done one by one, which can take years. The process was led by WHO with the participation of the African Vaccine Regulatory Forum (an African network of national regulatory authorities and ethics committees), the European Medicines Agency, and Merck.

    “The rapid approval of the Ebola vaccine by countries in the Africa Region helps ensure this critical prevention tool will be available when and where it is needed most,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “This kind of collaboration and innovation is a model for other health priorities.”

    The injectable Ebola vaccine, Ervebo, is manufactured by Merck (known as MSD outside the US and Canada). Preliminary study results have shown a 97.5% vaccine efficacy. Data also suggests that vaccinating people who are already infected reduces their chances of dying.

    In response to the ongoing Ebola outbreak in the DRC, over 290 000 people have been vaccinated under compassionate use protocols. Once licensed doses are available, use of the vaccine in DRC will no longer require these protocols

    Read More
    https://www.who.int/news-room/detail/14-02-2020-four-countries-in-the-african-region-license-vaccine-in-milestone-for-ebola-prevention

    Views: 0

  • World experts and funders set priorities for COVID-19 research

    World experts and funders set priorities for COVID-19 research

    Leading health experts from around the world have been meeting at the World Health Organization’s Geneva headquarters to assess the current level of knowledge about the new COVID-19 disease, identify gaps and work together to accelerate and fund priority research needed to help stop this outbreak and prepare for any future outbreaks.

    The 2-day forum was convened in line with the WHO R&D Blueprint – a strategy for developing drugs and vaccines before epidemics, and accelerating research and development while they are occurring.

    “This outbreak is a test of solidarity — political, financial and scientific. We need to come together to fight a common enemy that does not respect borders, ensure that we have the resources necessary to bring this outbreak to an end and bring our best science to the forefront to find shared answers to shared problems. Research is an integral part of the outbreak response,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus. “I appreciate the positive response of the research community to join us at short notice and come up with concrete plans and commitment to work together.”

    The meeting, hosted in collaboration with GloPID-R (the Global Research Collaboration for Infectious Disease Preparedness) brought together major research funders and over 300 scientists and researchers from a large variety of disciplines. They discussed all aspects of the outbreak and ways to control it including:

    • the natural history of the virus, its transmission and diagnosis;
    • animal and environmental research on the origin of the virus, including management measures at the human-animal interface;
    • epidemiological studies;
    • clinical characterization and management of disease caused by the virus;
    • infection prevention and control, including best ways to protect health care workers;
    • research and development for candidate therapeutics and vaccines;
    • ethical considerations for research;
    • and integration of social sciences into the outbreak response.

    “This meeting allowed us to identify the urgent priorities for research. As a group of funders we will continue to mobilize, coordinate and align our funding to enable the research needed to tackle this crisis and stop the outbreak, in partnership with WHO,” said Professor Yazdan Yazdanpanah, chair of GloPID-R. “Equitable access – making sure we share data and reach those most in need,  in particular those in lower and middle-income countries, is fundamental to this work which must be guided by ethical considerations at all times.”  

    During the meeting, the more than 300 scientists and researchers participating both in person and virtually agreed on a set of global research priorities. They also outlined mechanisms for continuing scientific interactions and collaborations beyond the meeting which will be coordinated and facilitated by WHO. They worked with research funders to determine how necessary resources can be mobilized so that critical research can start immediately.

    The deliberations will form the basis of a research and innovation roadmap charting all the research needed and this will be used by researchers and funders to accelerate the research response.

    Note to editors

    GloPID-R is a global alliance of international research funding organizations investing in preparedness and response to epidemics.

    World experts and funders set priorities for COVID-19 research
    Read More
    https://www.who.int/news-room/detail/12-02-2020-world-experts-and-funders-set-priorities-for-covid-19-research

    Views: 0